Advertisement
Screener

Allarity Therapeutics, Inc. (ALLR) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Allarity Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Allarity Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -1.66, a change of -1.05 year-over-year.
  • Allarity Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -1.55, a change of -0.87 year-over-year.
  • Allarity Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -1.55, a change of -1.21 year-over-year.
  • Allarity Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -1.64, a change of -1.33 year-over-year.
  • Allarity Therapeutics, Inc. pe ratio for fiscal 2026 was -1.66.
  • Allarity Therapeutics, Inc. pe ratio for fiscal 2025 was -1.55, a change of -1.21 from fiscal 2024.
  • Allarity Therapeutics, Inc. pe ratio for fiscal 2024 was -0.35, a change of -0.08 from fiscal 2023.
  • Allarity Therapeutics, Inc. pe ratio for fiscal 2023 was -0.27, a change of 174.37 from fiscal 2022.
Available history
2021-12-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-1.66$20.52M-$12.33M
2026-03-31-1.55$17.48M-$11.25M
2025-12-31-1.55$17.45M-$11.23M
2025-09-30-1.64$25.13M-$15.31M
2025-06-30-0.61$14.77M-$24.1M
2025-03-31-0.68$15.95M-$23.4M
2024-12-31-0.35$8.54M-$24.52M
2024-09-30-0.31$5.82M-$18.78M
2024-06-30-19.23$223.9M-$11.64M
2024-03-31-3.33$41.26M-$12.39M
2023-12-31-0.27$3.24M-$11.9M
2023-09-30-144.12$1.88B-$13.02M
2023-06-30-146.56$1.99B-$13.61M
2023-03-31-2,934.22$47.92B-$16.33M
2022-12-31-174.65$2.8B-$16.06M
2022-09-30-315,623.57$9.48T-$30.04M
2022-06-30-390,623.41$10.29T-$26.35M
2022-03-31-568,688.94$15.15T-$26.64M
2021-12-31-2,647,632.63$70.56T-$26.65M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-1.66$20.52M-$12.33M
2025-12-31-1.55$17.45M-$11.23M
2024-12-31-0.35$8.54M-$24.52M
2023-12-31-0.27$3.24M-$11.9M
2022-12-31-174.65$2.8B-$16.06M
2021-12-31-2,647,632.63$70.56T-$26.65M

Similar stocks

Stock NameCountryMarket CapPE Ratio
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B